![]() |
市場調查報告書
商品編碼
1725188
痔瘡治療市場預測至 2032 年:按產品類型、治療類型、疾病類型、分銷管道、最終用戶和地區進行的全球分析Hemorrhoid Treatment Market Forecasts to 2032 - Global Analysis By Product Type, Treatment Type, Disease Type, Distribution Channel, End User and By Geography |
根據 Stratistics MRC 的數據,全球痔瘡治療市場預計在 2025 年達到 12 億美元,到 2032 年將達到 20.7 億美元,預測期內的複合年成長率為 8.10%。
痔瘡治療是指對直腸和肛門內腫脹和發炎的靜脈(通常稱為痔瘡)進行藥物治療或手術治療。治療方案取決於嚴重程度,可能包括改變生活方式,例如增加纖維攝取量以促進排便和飲用足夠的液體。非處方藥膏、軟膏和塞劑可以幫助緩解搔癢和不適。在更嚴重的情況下,可以進行橡皮筋結紮、硬化療法和紅外線凝固等手術。在極少數情況下,可能需要手術切除(切除術)。早期治療和預防護理對於緩解症狀、改善生活品質和避免出血和感染等併發症至關重要。
根據美國衛生研究院(NIH)2021年發表的一篇論文,全球一般人群痔瘡盛行率估計為4.4%。
痔瘡盛行率不斷上升
痔瘡盛行率的上升極大地推動了痔瘡治療市場的成長。久坐的生活方式、人口老化和飲食習慣等因素導致病例增加,增加了對有效治療的需求。這種普及促進了微創手術和商業化產品的進步,提高了患者的可及性和舒適度。此外,人們意識的提高和恥辱感的減少正在鼓勵更多的人尋求醫療干預,從而進一步擴大市場。
社會恥辱與尷尬
痔瘡治療與羞恥和社會恥辱有關,這嚴重阻礙了市場的成長。相當多的人不願意尋求治療,因為他們認為這是一種社會禁忌,並且不願意談論此類症狀。這導致診斷和治療被推遲,從而減少了對痔瘡相關服務和產品的需求。這種危害在保守社會中尤其明顯,人們可能會選擇自我護理或忽視症狀,這限制了市場潛力並阻礙了有效治療方法的採用。
非處方藥的供應
由於非處方藥 (OTC) 的可用性、可負擔性以及消費者的自主性,痔瘡治療市場蓬勃發展。無需處方箋即可購買的產品(例如藥膏和塞劑)可以輕鬆、非侵入性地緩解症狀。這鼓勵自我治療並減少痔瘡的羞恥感。這一趨勢是由零售店和網路藥局的成長所推動的,它們允許謹慎購買並有助於擴大市場。此外,人們的健康意識不斷增強,推動了非處方藥需求的增加,刺激了技術創新和製造商之間的競爭。
醫療費用高昂
痔瘡治療市場受到高昂治療費用的不利影響,這限制了許多人獲得治療的機會,尤其是在新興市場。這些費用可能會阻止患者尋求及時治療,可能導致症狀和併發症惡化。此外,治療費用可能無法完全由保險承擔,這阻礙了市場的成長。因此,患者可能會轉向較便宜但效果較差的治療方案,進而影響整體治療接受率。
COVID-19的影響
由於醫療資源被重新用於對抗病毒,COVID-19 疫情對痔瘡治療市場產生了重大影響。許多選擇性手術,包括痔瘡手術,都被延遲或取消,導致護理需求減少。然而,遠端醫療的興起提供了替代方案,隨著醫療保健系統適應新常態,市場逐漸復甦。
預測期內,血栓性痔瘡預計將成為最大的細分市場
由於醫療干預的緊迫性,通常需要手術或微創手術,預計血栓性痔瘡將在預測期內佔據最大的市場佔有率。診斷率的上升和患者尋求治療的意願的增強正在推動對先進治療的需求。非侵入性治療和疼痛管理方案的創新將進一步推動市場成長。血栓性痔瘡常常引起嚴重的症狀,導致醫療專業人員的數量增加,大大促進了整個痔瘡治療市場的擴張。
預計在預測期內,醫院部門的複合年成長率最高。
由於擁有先進的醫療基礎設施、熟練的醫務人員和微創手術,預計醫院部門將在預測期內實現最高成長。該醫院將作為主要的診斷和治療中心,確保患者得到及時和準確的治療。此外,因手術和非手術痔瘡治療而入院的人數不斷增加也推動了需求的成長。將尖端技術與全面的術後護理相結合,進一步改善治療效果,使醫院成為市場擴張的主要貢獻者。
在預測期內,由於人們對肛門健康的認知不斷提高、醫療保健基礎設施不斷改善以及對微創治療的需求不斷增加,預計亞太地區將佔據最大的市場佔有率。人口老化、久坐的生活方式和飲食習慣導致痔瘡患病率上升,從而推動了市場擴張。政府和私人公司正在投資先進的醫療技術和推廣計劃,以改善患者的治療效果和獲得醫療服務的機會。這種成長正在推動創新並加強該地區的整體醫療保健生態系統。
預計北美地區在預測期內將呈現最高的複合年成長率。這是由於老年人口不斷成長以及先進的微創治療方案的出現。技術進步、醫療支出的增加以及醫療設施的改善提高了早期診斷和有效管理。此外,優惠的報銷政策和主要市場參與者的強大影響力正在推動市場成長,而與生活方式相關的風險因素則進一步刺激需求,整體上形成了充滿活力且不斷擴大的治療格局。
According to Stratistics MRC, the Global Hemorrhoid Treatment Market is accounted for $1.20 billion in 2025 and is expected to reach $2.07 billion by 2032 growing at a CAGR of 8.10% during the forecast period. Hemorrhoid treatment refers to the medical or surgical management of swollen and inflamed veins in the rectum or anus, commonly known as piles. Treatment options vary depending on severity and may include lifestyle changes, such as increased fiber intake and proper hydration, to ease bowel movements. Over-the-counter creams, ointments, and suppositories can reduce itching and discomfort. For more severe cases, procedures like rubber band ligation, sclerotherapy, or infrared coagulation may be performed. In rare cases, surgical removal (hemorrhoidectomy) is necessary. Early treatment and preventive care are essential to alleviate symptoms, improve quality of life, and avoid complications such as bleeding or infection.
according to an article published by the National Institutes of Health (NIH) in 2021, the estimated worldwide prevalence of hemorrhoids in the general population was estimated to be 4.4%.
Rising Prevalence of Hemorrhoids
The rising prevalence of hemorrhoids is significantly propelling the growth of the hemorrhoid treatment market. Factors such as sedentary lifestyles, aging populations, and dietary habits contribute to increased cases, leading to heightened demand for effective treatments. This surge has spurred advancements in minimally invasive procedures and over-the-counter products, enhancing patient accessibility and comfort. Additionally, growing awareness and reduced stigma encourage more individuals to seek medical intervention, further expanding the market.
Social Stigma and Embarrassment
The treatment of hemorrhoids is associated with feelings of shame and social stigma, and this serves to greatly impede the growth of the market. A significant number of people refrain from pursuing treatment because they perceive a social taboo and feel uneasy about talking about such conditions. This hesitance postpones diagnosis and therapy, leading to a decreased need for hemorrhoid-related services and products. This detrimental effect is particularly evident in conservative societies, where people might choose self-care or overlook symptoms, thus constraining market potential and hindering the adoption of effective treatments.
Availability of Over-the-Counter (OTC) Medications
The hemorrhoid treatment market has been significantly advanced by the accessibility, affordability, and consumer autonomy provided by over-the-counter (OTC) medications. Products available without a prescription, such as ointments and suppositories, provide simple and non-invasive relief. This fosters self-treatment and diminishes the stigma around hemorrhoids. The growth of retail and online pharmacies, which allow for discreet purchases and contribute to market expansion, supports this trend. Furthermore, the growing health consciousness have resulted in a heightened demand for OTC options, prompting innovation and rivalry among producers.
High Treatment Costs
The market for hemorrhoid treatment is adversely affected by the high costs of treatment, which restrict accessibility for a large segment of the population, especially in developing areas. These costs can discourage patients from pursuing prompt medical treatment, resulting in aggravated symptoms or complications. Furthermore, the costs of treatment might not be completely compensated by insurance coverage, which hampers market growth. Consequently, patients might resort to less costly but also less effective options, which impacts the overall rates of treatment adoption.
Covid-19 Impact
The COVID-19 pandemic significantly impacted the hemorrhoid treatment market as healthcare resources were redirected towards combating the virus. Many elective procedures, including hemorrhoid surgeries, were postponed or canceled, leading to a decline in treatment demand. However, the rise in telemedicine and at-home treatments, such as over-the-counter medications and non-invasive therapies, provided an alternative, helping the market recover gradually as healthcare systems adapted to the new normal.
The thrombosed hemorrhoids segment is expected to be the largest during the forecast period
The thrombosed hemorrhoids segment is expected to account for the largest market share during the forecast period, due to its urgent need for medical intervention, often requiring surgical or minimally invasive procedures. Rising diagnosis rates, and greater patient willingness to seek treatment are boosting demand for advanced therapies. Innovations in non-invasive treatments and pain management options further enhance market growth. As thrombosed hemorrhoids often present with severe symptoms, they lead to higher healthcare engagement, significantly contributing to the overall expansion of hemorrhoid treatment market.
The hospitals segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the hospitals segment is predicted to witness the highest growth rate, due to advanced medical infrastructure, skilled healthcare professionals, and the availability of minimally invasive procedures. Hospitals serve as primary centers for diagnosis and treatment, ensuring timely and accurate care for patients. Additionally, increasing patient admissions for surgical and non-surgical hemorrhoid treatments boost demand. The segment's integration of cutting-edge technologies and comprehensive postoperative care further enhances treatment outcomes, positioning hospitals as key contributors to the market's expansion.
During the forecast period, the Asia Pacific region is expected to hold the largest market share due to rising awareness of anorectal health, improving healthcare infrastructure, and increasing demand for minimally invasive treatments. Aging populations, sedentary lifestyles, and dietary habits have contributed to a higher incidence of hemorrhoids, fueling market expansion. Governments and private players are investing in advanced medical technologies and outreach programs, enhancing patient outcomes and access to care. This growth is fostering innovation and strengthening the region's overall healthcare ecosystem.
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to increasing geriatric population, and the availability of advanced, minimally invasive treatment options. Technological advancements, growing healthcare expenditure, and improved access to medical facilities are enhancing early diagnosis and effective management. Additionally, favorable reimbursement policies and strong presence of key market players are accelerating market growth, while lifestyle-related risk factors further fuel demand, collectively shaping a dynamic and expanding treatment landscape.
Key players in the market
Some of the key players profiled in the Hemorrhoid Treatment Market include Johnson & Johnson, Bausch Health Companies Inc., Pfizer Inc., Church & Dwight Co., Inc., Takeda Pharmaceutical Company Limited, Sanofi, GlaxoSmithKline plc, AbbVie Inc., Novartis AG, Bayer AG, Reckitt Benckiser Group plc, Sun Pharmaceutical Industries Limited, Cipla Ltd., Dr. Reddy's Laboratories Ltd., Glenmark Pharmaceuticals Limited, Perrigo Company plc, Proctortec Ltd., Medtronic plc and Boston Scientific Corporation.
In April 2025, ConcertAI announced a multi-year strategic agreement with Bayer AG aimed at accelerating clinical development in precision oncology. Through this partnership, Bayer will leverage ConcertAI's Translational360(TM) platform and AI SaaS solutions, which integrate multi-modal real-world data-including clinical, genomic, transcriptomic, and imaging data-to enhance oncology research and development.
In February 2025, Planet Labs PBC and Bayer have expanded their strategic partnership through a multi-year enterprise license agreement, enhancing Bayer's access to Planet's satellite imagery and analytics. This collaboration aims to accelerate digital innovation in agriculture by enabling Bayer to make data-driven decisions across its global operations.
In October 2024, Bayer and MOMA Therapeutics have entered into a collaboration and exclusive license agreement to develop and commercialize a small molecule oncology program utilizing MOMA's proprietary KNOMATIC(TM) platform. This partnership aims to advance precision oncology treatments by targeting highly dynamic proteins, which are emerging as critical players in cancer progression.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.